BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority ReviewBy Nasdaq OMXMar 21, 2016, 8:05 PM UTC
BusinessRaptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ETBy Nasdaq OMXFeb 18, 2016, 12:30 PM UTC
BusinessFour New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan ExclusivityBy Nasdaq OMXJan 25, 2016, 12:05 PM UTC
